Therapeutic Goods (Medicines Watch List) Determination 2018

Overview

The Therapeutic Goods (Medicines Watch List) Determination 2018 was enacted under subsection 30EJ(1) of the Therapeutic Goods Act 1989 by the Parliament of Australia to address the need for a formalised list of medicines that require monitoring and reporting due to their significant health risks or critical use in medical treatments. The Determination identifies specific medicines, including antimicrobial agents, antidotes, vaccines, and emergency medications, which are to be included in a Medicines Watch List for regulatory oversight. This list is instrumental in enhancing pharmacovigilance and ensuring the safe use of therapeutic goods by mandating the reporting of adverse effects and other critical data associated with these medicines. The objective of this legislation is to bolster the oversight and management of therapeutic goods within Australia, aiming to protect public health by ensuring that healthcare professionals and regulatory bodies are adequately informed about the risks and benefits of certain medications.

Scope and Application

The Therapeutic Goods (Medicines Watch List) Determination 2018 applies to medicines listed in the Schedule of the Determination, which are designated as reportable medicines under the Therapeutic Goods Act 1989. This legislation mandates that these specified medicines be included in a Medicines Watch List, facilitating the monitoring and reporting of adverse events and other critical information associated with these therapeutic products. The Determination extends to all entities and persons involved in the manufacture, supply, or administration of these medicines within Australia, encompassing both Commonwealth and state jurisdictions. The Determination does not specify exclusions, but it is implicit that only the listed medicines are subject to the requirements of the Watch List. The application and scope of the Determination can be further refined or extended through subordinate instruments, which may specify additional details or modify the list of reportable medicines. This legislative instrument operates nationally across Australia, ensuring a coordinated approach to medicine safety and vigilance.

Key Provisions

The Therapeutic Goods (Medicines Watch List) Determination 2018 (sections 1 and 5) sets out the list of reportable medicines that must be monitored under the Therapeutic Goods Act 1989 (the Act). This list, detailed in Schedule 1, includes specific antimicrobial agents, antidotes, emergency and critical care medicines, anticoagulants, vaccines, obstetrics medicines, antivenoms, and other specific medicines such as adrenaline autoinjectors and naloxone. These medicines are identified based on their critical therapeutic roles and potential risks, necessitating close monitoring to ensure public safety. The Act, through this determination, imposes several obligations on entities involved in the manufacture, supply, or distribution of these listed medicines. These obligations include the requirement to report adverse events and other relevant information to the Therapeutic Goods Administration (TGA). Additionally, the Act mandates that entities must comply with any additional monitoring or reporting requirements specified by the TGA to ensure that the risks associated with these medicines are effectively managed. Violations of the reporting requirements or other obligations under the Act may result in civil or criminal penalties. The Act provides for maximum penalties for serious breaches, including fines and imprisonment. For instance, section 30EH of the Act stipulates that an individual who contravenes a provision of the Act may be subject to a fine of up to $1,100,000, and in the case of a body corporate, the fine can be as high as $5,500,000. Furthermore, imprisonment terms are also applicable, with maximum penalties reaching up to five years for individuals and ten years for body corporates, depending on the severity of the breach. It is also important to note that the Act includes provisions for administrative penalties and compliance orders, which the TGA can impose for less severe breaches. These penalties are intended to encourage compliance and deter non-compliance with the reporting and monitoring requirements set out in the Act. The TGA has the authority to issue infringement notices for minor breaches, which can result in fines without the need for court proceedings. For more serious breaches, the TGA can apply to the Federal Court for compliance orders or seek prosecution, which can lead to significant penalties as outlined in the Act.